- Investing.com
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
तुलना करने के लिए मीट्रिक्स | NMTRQ | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत वित्तीय | संबंध संबंधNMTRQपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 0.0x | −0.4x | −0.6x | |
PEG अनुपात | 0.00 | −0.01 | 0.00 | |
क़ीमत/बुक | 0.0x | 0.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.0x | 0.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 0.0% | 159.8% | 55.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.8% | 6.9% | अनलॉक करें |